Back to News
Health & Wellness
Nov 15, 202625 views2 min read

FDA Requires GLP-1 Drug Labels to Warn of Rare Vision Loss Risk

The FDA announced on November 9, 2026, that all GLP-1 medications must now carry warnings about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause permanent vision loss. The decision followed a two-year review of clinical and real-world data. Experts say the absolute risk remains low and advise patients not to stop treatment without consulting their doctors.

FDA Requires GLP-1 Drug Labels to Warn of Rare Vision Loss Risk
Source:FDA

The U.S. Food and Drug Administration announced on November 9, 2026, that manufacturers of all GLP-1 receptor agonist medications must add warnings about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, known as NAION, to their product labels.

NAION is a rare condition involving reduced blood flow to the optic nerve. It can cause sudden, painless, and potentially permanent vision loss in one eye.

The FDA's decision followed a two-year review of clinical trial data, animal studies, and real-world evidence. The review was triggered by a 2024 study that suggested a possible link between semaglutide, the active ingredient in Ozempic and Wegovy, and NAION.

A meta-analysis of 126 randomized clinical trials covering more than 134,000 patients found 6.4 NAION cases per 100,000 person-years among GLP-1 users, compared to 3.8 per 100,000 person-years for those on a placebo or non-GLP-1 medication. The FDA noted that available animal data did not identify a clear biological mechanism for the association.

The agency is requiring the warning to appear in the "Warnings and Precautions" section of all GLP-1 drug labels. Manufacturers including Novo Nordisk and Eli Lilly acknowledged the FDA communication. Some have maintained that existing data do not definitively establish a cause-and-effect relationship.

The FDA advises health care professionals to inform patients of the potential risk and tell them to seek immediate medical attention if they experience sudden vision changes. Patients with a prior history of NAION are at higher risk of recurrence.

Experts emphasize that the absolute risk of NAION remains very low. Patients are generally advised not to stop GLP-1 treatment without first consulting their physicians, as the medications provide significant benefits for diabetes management and weight loss.

Related Articles